دورية أكاديمية
أعرض في EDS

Relationship between CD4 count and quality of life over time among HIV patients in Uganda: a cohort study.

التفاصيل البيبلوغرافية
العنوان: Relationship between CD4 count and quality of life over time among HIV patients in Uganda: a cohort study.
المؤلفون: Mwesigire DM; Department of Medicine, Makerere College of Health Sciences, PO Box 7072, Kampala, Uganda. dorismutabazi@yahoo.com., Martin F; Department of Psychology, University of Bath, Bath, United Kingdom. psmfm@bath.ac.uk., Seeley J; MRC/UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda. janet.seeley@mrcuganda.org., Katamba A; Department of Medicine, Makerere College of Health Sciences, PO Box 7072, Kampala, Uganda. akatamba@yahoo.com.
المصدر: Health and quality of life outcomes [Health Qual Life Outcomes] 2015 Sep 15; Vol. 13, pp. 144. Date of Electronic Publication: 2015 Sep 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525 (Electronic) Linking ISSN: 14777525 NLM ISO Abbreviation: Health Qual Life Outcomes Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2003-
مواضيع طبية MeSH: CD4 Lymphocyte Count*, Antiretroviral Therapy, Highly Active/*psychology , HIV Infections/*drug therapy , HIV Infections/*psychology , Quality of Life/*psychology, Adult ; Aged ; Antiretroviral Therapy, Highly Active/statistics & numerical data ; Cohort Studies ; Disease Progression ; Female ; Health Surveys ; Humans ; Male ; Mental Health ; Middle Aged ; Outcome Assessment, Health Care ; Socioeconomic Factors ; Uganda
مستخلص: Background: Immunological markers (CD4 count) are used in developing countries to decide on initiation of antiretroviral therapy and monitor HIV/AIDS disease progression. HIV is an incurable chronic illness, making quality of life paramount. The direct relationship between quality of life and CD4 count is unclear. The purpose of this study is to determine the relationship between change in CD4 count and quality of life measures in a Ugandan cohort of people living with HIV.
Methods: We prospectively assessed quality of life among 1274 HIV patients attending an HIV clinic within a national referral hospital over a period of 6 months. Quality of life was measured using an objective measure, the Medical Outcomes Study HIV health survey summarized as Physical Health Score and Mental Health Score and a subjective measure, the Global Person Generated Index. Generalized estimating equations were used to analyze the data. The primary predictor variable was change in CD4 count, and the outcome was quality of life scores. We controlled for sociodemographic characteristics, clinical factors and behavioral factors. Twenty in-depth interviews were conducted to assess patient perception of quality of life and factors influencing quality of life.
Results: Of the 1274 patients enrolled 1159 had CD4 count at baseline and six months and 586 (51%) received antiretroviral therapy. There was no association found between change in CD4 count and quality of life scores at univariate and multivariate analysis among the study participants whether on or not on antiretroviral therapy. Participants perceived quality of life as happiness and well-being, influenced by economic status, psychosocial factors, and health status.
Conclusions: Clinicians and policy makers cannot rely on change in immunological markers to predict quality of life in this era of initiating antiretroviral therapy among relatively healthy patients. In addition to monitoring immunological markers, socioeconomic and psychosocial factors should be underscored in management of HIV patients.
References: AIDS. 2000 Jan 28;14(2):181-7. (PMID: 10708289)
Med Care. 2000 Apr;38(4):404-10. (PMID: 10752972)
AIDS. 2000 Jul 7;14(10):1449-51. (PMID: 10930161)
Pharmacoeconomics. 2000 Jul;18(1):63-72. (PMID: 11010605)
Qual Life Res. 2000;9(9):977-85. (PMID: 11332226)
Clin Infect Dis. 2001 Oct 15;33(8):1417-23. (PMID: 11550118)
J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):485-92. (PMID: 12154339)
AIDS Care. 2003 Aug;15(4):581-90. (PMID: 14509872)
AIDS Care. 2004 Jan;16(1):81-94. (PMID: 14660146)
J Clin Epidemiol. 2004 Mar;57(3):259-67. (PMID: 15066686)
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1100-2. (PMID: 15247564)
Med Care. 1991 Aug;29(8):786-98. (PMID: 1875745)
Med Care. 1994 Nov;32(11):1109-26. (PMID: 7967852)
N Engl J Med. 1996 Feb 15;334(7):426-31. (PMID: 8552144)
Qual Life Res. 1996 Feb;5(1):47-55. (PMID: 8901366)
Ann Intern Med. 1997 Jun 15;126(12):946-54. (PMID: 9182471)
Qual Life Res. 1997 Aug;6(6):481-93. (PMID: 9330549)
Med Care. 1998 Feb;36(2):126-37. (PMID: 9475468)
BMJ. 1998 Jun 13;316(7147):1827. (PMID: 9624085)
AIDS. 1998 Aug 20;12(12):1495-502. (PMID: 9727571)
Pharmacoeconomics. 1999 Feb;15(2):141-55. (PMID: 10351188)
AIDS Patient Care STDS. 2005 Jun;19(6):395-405. (PMID: 15989435)
AIDS Care. 2005 Jul;17(5):579-88. (PMID: 16036244)
HIV Clin Trials. 2005 May-Jun;6(3):127-35. (PMID: 16192247)
AIDS Behav. 2006 Jul;10(4 Suppl):S105-11. (PMID: 16802195)
Qual Life Res. 2006 Dec;15(10):1597-605. (PMID: 17033910)
AIDS Care. 2007 May;19(5):626-36. (PMID: 17505923)
Qual Life Res. 2007 Aug;16(6):961-8. (PMID: 17468942)
Health Qual Life Outcomes. 2003;1:12. (PMID: 12773200)
JAMA. 2008 Nov 5;300(17):2054-6. (PMID: 18984895)
AIDS Care. 2009 Mar;21(3):271-9. (PMID: 19280404)
AIDS Patient Care STDS. 2009 Jul;23(7):563-70. (PMID: 19534603)
AIDS Care. 2009 Jun;21(6):742-53. (PMID: 19806490)
AIDS Care. 2009 Dec;21(12):1517-27. (PMID: 20024731)
Health Qual Life Outcomes. 2009;7:105. (PMID: 20040090)
BMC Psychiatry. 2010;10:44. (PMID: 20537129)
AIDS Care. 2010;22 Suppl 1:44-50. (PMID: 20229371)
HIV Med. 2011 Jan;12(1):22-30. (PMID: 20497251)
Qual Life Res. 2012 Nov;21(9):1655-63. (PMID: 22198741)
SAHARA J. 2013 Mar;10(1):25-31. (PMID: 23777555)
BMC Public Health. 2014;14:343. (PMID: 24721338)
BMC Public Health. 2014;14:676. (PMID: 24990360)
HIV Clin Trials. 2014 Jul-Aug;15(4):176-83. (PMID: 25143026)
BMC Public Health. 2014;14:1035. (PMID: 25280535)
Pan Afr Med J. 2014;18:234. (PMID: 25426192)
Biomed Res Int. 2015;2015:516369. (PMID: 25632393)
BMC Infect Dis. 2014;14:613. (PMID: 25403371)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; MC_U950097150 United Kingdom MRC_ Medical Research Council
تواريخ الأحداث: Date Created: 20150916 Date Completed: 20160303 Latest Revision: 20240323
رمز التحديث: 20240323
مُعرف محوري في PubMed: PMC4570610
DOI: 10.1186/s12955-015-0332-3
PMID: 26370702
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-7525
DOI:10.1186/s12955-015-0332-3